Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB242 vs Infliximab in Rheumatoid Arthritis
NCT04178850Phase 3Unknown
- Sponsor
- Genor Biopharma
- Start
- Oct 2017
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of infliximab-axxq in rheumatoid arthritis (RA) (2 arms), sponsored by Genor Biopharma. Primary endpoint: American College of Rheumatology 20% Response at 30 weeks. Status: unknown.
02
Drugs
infliximab-axxq
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04178850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04178850.